Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-12

Clinical Trial Update: A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder [Phase 3]

View source ↗

Summary

Phase 3 safety study of flibanserin in pre- and postmenopausal women with hypoactive sexual desire disorder was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Flibanserin (Flibanserin)

Snippet

Sponsor: Sprout Pharmaceuticals, Inc | Conditions: Sexual Dysfunctions, Psychological | Phase 3 | Status: TERMINATED | Results posted: 2014-05-12